The Cancer Letter

Inside information on cancer research and drug development

Vol.
44
No.
40
October 26, 2018Oct 26, 2018
DOWNLOAD THE PDF
Long-awaited trial of checkpoint inhibitor in breast cancer produces 2-month PFS gain; no final OS advantage seen—yet
Cover Story

Long-awaited trial of checkpoint inhibitor in breast cancer

produces 2-month PFS gain; no final OS advantage seen—yet
By Matthew Bin Han Ong
Tecentriq, Genentech's PD-L1 checkpoint inhibitor, is the first immunotherapy agent to report positive outcomes in breast cancer in a phase III trial—providing proof of principle that these drugs are active in treatment of triple-negative breast cancer.
NCI's Korde: Follow-up needed to validate PFS with mature OS results for Tecentriq
Conversation with The Cancer Letter
By Matthew Bin Han Ong
Has Tecentriq earned a role in treatment of triple-negative breast cancer? Here is what experts say
Trump's drug pricing plan pegs Medicare Part B payments to international levels
By Paul Goldberg

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account